One in 10 Korean adults has used glucagon-like peptide-1 weight-loss medications over the past year, with younger generations driving both current consumption and future demand, The Korea Herald reported.
- Demographic Shift: Usage is heavily concentrated among younger adults, contrasting sharply with older cohorts.
- Continued Demand: A clear majority of past users intend to keep taking the drugs, pointing to sustained reliance on these therapies.
The 2026 Korea Wellness Report by KB Financial Group Research Institute shows that 10.3 percent of survey respondents had been prescribed or used GLP-1 weight-loss drugs. The survey covered 2,000 adults aged 25 to 69.
Gen Z respondents—defined as those born in 1995 or later—reported the highest usage rate at 16.5 percent. Millennial usage followed at 14.2 percent, while Gen X reported 7.7 percent and baby boomers recorded 2.9 percent.
| Demographic Cohort | Reported Usage Rate | Future Intent to Use |
|---|---|---|
| Gen Z (1995 and later) | 16.5% | 39.7% |
| Millennials | 14.2% | Not specified |
| Gen X | 7.7% | Not specified |
| Baby Boomers | 2.9% | Not specified |
Men reported higher actual usage than women, at 11.6 percent compared to 9 percent. Conversely, awareness of the medications ran higher among women at 83.1 percent, while male awareness stood at 73 percent.
Future interest in starting the treatments remains substantial across the broader adult population. About 33.9 percent of respondents expressed a willingness to use the drugs in the future, a figure that climbs to 39.7 percent specifically among Gen Z participants.
Among those who have already used the medications, 65.5 percent stated an intention to continue their regimen.
- KB Financial Group Research Institute. 2026 Korea Wellness Report.
- The Korea Herald reported that 1 in 10 Korean adults have used weight-loss drugs.